Two of India's top drugmakers are grappling with product recalls after regulators in the U.S. spotted signs of impurities in their drugs. Sun Pharmaceuticals is recalling about 155,000 bottles of an eye solution, while two of Cipla's top pharma partners have pulled products made at its Goa plant.
Sun had to start pulling back its eye solution for conjunctivitis after regulators discovered the presence of impurities, according to an FDA inspection report. The solution is made at a Sun facility in Gujarat. Sun says it has identified the causes of the problem and put corrective action in motion.
Cipla says that Teva ($TEVA) is recalling more than 7,000 bottles of flutamide--a prostate cancer therapy--after inspectors found signs of another cancer medicine in some of its supplies. And Eagle Pharmaceuticals is voluntarily recalling a quantity of argatroban injection, an anticoagulant, after crystalline particulates were found in the supply. Both drugs are made at Cipla's plant in Goa.
FDA brings Sun's Doxil copy online to fix shortage
Sun to market Merck diabetes drugs in India
Indian regulators, alleging overpricing, demand $86M from Cipla
Cipla eyes alliances to grow in emerging markets